Introduction
Neuropathic pain is a debilitating chronic pain condition, but available pharmacotherapies lack efficacy and are associated with various adverse side-effects (Nightingale, 2012) . Monoacylglycerol lipase (MAGL), the major serine hydrolase responsible for degradation of the most abundant endocannabinoid in the central nervous system, 2-arachidonoylglycerol (2-AG) (Dinh et al., 2002) , represents a promising target for the treatment of neuropathic pain and other pain-related therapeutic indications. MAGL inhibitors block 2-AG degradation leading to increased levels of this endocannabinoid and consequently lead to increased signaling at cannabinoid CB 1 and CB 2 receptors. Initial compounds used to inhibit MAGL in whole animals, such as methylarachidonylfluorophosphonate and N-arachidonyl maleimide have poor selectivity when administered systemically (Makara et al., 2005; Saario et al., 2005; Burston et al., 2008) , which makes it difficult to discern whether the observed pharmacological effects were due to MAGL inhibition, off-target actions (e.g., another serine hydrolase), or combination of MAGL inhibition and off-target effects. While an in vitro study showed that URB602 lacks selectivity between MAGL and FAAH (Vandevoorde et al., 2007) , in vivo studies found that intracerebral (Hohmann et al., 2005) , systemic (Wiskerke et al., 2012) , or intraplantar (Guindon et al., 2011) URB602 administration raises 2-AG levels, but not AEA levels.
The recent development of MAGL inhibitors with increased selectivity compared with previous compounds has provided useful tools to investigate consequences of inhibiting this enzyme in the whole animal. Results from several preclinical studies employing the first selective MAGL inhibitor, JZL184 (Long et al., 2009a) , suggested that this enzyme represents a unique target to treat pain-related conditions. Acute administration of JZL184 was reported to reduce nociception in acetic acid-induced abdominal stretching, the carrageenan model of inflammatory pain, the chronic constrictive injury of the sciatic nerve (CCI) model, cisplatinThis article has not been copyedited and formatted. The final version may differ from this version.
JPET Fast Forward. Published on as DOI: 10.1124 at ASPET Journals on September 13, 2017 jpet.aspetjournals.org Downloaded from JPET #222315 5 induced neuropathy model, and capsaicin-induced behavioral sensitization (Kinsey et al., 2009; Long et al., 2009a; Guindon et al., 2010; Spradley et al., 2010; Ghosh et al., 2013; Kinsey et al., 2013) . Importantly, JZL184 elicited a decreased spectrum of other cannabimimetic effects associated with Δ 9 -tetrahydrocannabinol (THC) and other CB 1 receptor agonists. Although JZL184 is approximately 450 fold more selective in inhibiting MAGL than fatty acid amide hydrolase (FAAH) and does not alter AEA brain levels upon acute administration, repeated administration of high dose produces a 2-3 fold increase in this endocannabinoid (Schlosburg et al., 2010) . Another limitation of JZL184 is its decreased potency in inhibiting rat MAGL activity (IC 50 value = 262 nM) compared with mouse MAGL activity (IC 50 value = 10 nM) (Chang et al., 2012) . MJN110, another recently developed selective MAGL inhibitor, showed markedly increased potency in rat and no significant cross-reactivity with FAAH (Niphakis et al., 2013) .
These compounds provide tools to compare the pharmacological effects of structurally distinct MAGL inhibitors in preclinical animal models of pain and assays indicative of cannabimimetic activity (e.g., drug discrimination, hypothermia, catalepsy, and hypomotility).
The primary purpose of the present study was to compare directly the pharmacological effects of JZL184 and MJN110 in the chronic constriction nerve injury (CCI) model of neuropathic pain as well as in assays indicative of cannabimimetic effects. JZL184 has already been shown to reduce allodynia in the CCI model of neuropathic pain (Kinsey et al., 2009; Kinsey et al., 2013) . MJN110 reduces nociception in a rat diabetic neuropathy model (Niphakis et al., 2013) , but has yet to be tested in the CCI model. A major challenge in developing directacting CB 1 receptor agonists as therapeutic agents is their cannabimimetic side effects. Although JZL184 administered in a vehicle consisting of alkamuls-620, ethanol, and saline did not elicit common cannabimimetic effects (i.e., catalepsy and hypothermia), it produced others (i.e., decreased locomotor activity and partial substitution for THC in the drug discrimination paradigm) (Long et al., 2009b; Long et al., 2009c) . In contrast, MJN110 remains to be assessed. This article has not been copyedited and formatted. The final version may differ from this version.
JPET Fast Forward. Published on as DOI: 10.1124 at ASPET Journals on September 13, 2017 jpet.aspetjournals.org Downloaded from JPET #222315 6 Thus, the second objective of this study was to compare the cannabimimetic "side effect" profile of these drugs, with an emphasis on locomotor activity, and interoceptive effects assessed in the drug discrimination paradigm. Additionally, we tested whether MJN110 produces other common cannabimimetic actions, including antinociception in the tail withdrawal assay, catalepsy in the bar test, and hypothermia. Finally, we quantified whole brain levels of 2-AG as well as arachidonic acid. Of note, MAGL serves as a major biosynthetic enzyme of arachidonic acid in brain . Because JZL184 also inhibits FAAH, we also quantified brain levels of the prevalent FAAH substrates AEA and noncannabinoid fatty acid amides (i.e., palmitoylethanolamide (PEA) and oleoylethanolamide (OEA)).
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Methods

Animals
Male C57BL/6J mice (Jackson Laboratory, Bar Harbor, ME) were used in all experiments. Body mass of mice ranged from 18 to 35 g. Four to five mice were housed per cage in all experiments, except in the drug discrimination experiments, in which subjects were singly housed. Animals were maintained in a 12/12 h light/dark cycle (0600 h on/ 1800 h off) in a temperature (20-22 °C) and humidity (55 ± 10 %) controlled AAALAC-approved facility.
Animals had ad libitum access to water and food, with the exception of animals used in drug discrimination experiments, which were food restricted to 85-90 % of free feeding body weight.
All tests were conducted during the light phase. The sample sizes selected for each treatment group in each experiment were based on previous studies from our laboratory.
All animal protocols were approved by the Institutional Animal Care and Use Committee at Virginia Commonwealth University and were in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals (National Research Council, 2011) .
Drugs
MJN110 was synthesized in the Cravatt laboratory at the Scripps Research Institute as described previously (Chang et al., 2012; Niphakis et al., 2013) . JZL184 (Long et al., 2009a) , the 
Behavioral assessment of nociceptive behavior
Mechanical allodynia and thermal hyperalgesia were used to assess nociceptive behavior following sham or CCI surgery (see below). Prior to surgery, mice were habituated to the testing environment, and then von Frey monofilaments (North Coast Medical, Morgan Hills, CA) were used to establish baseline (BL) responses to light mechanical touch and to assess the development and presence of allodynia after surgery (Murphy et al., 1999) . Specifically, the mice were placed on top of a wire mesh screen, with spaces 0. 9
Chronic constriction injury (CCI) surgery
Following baseline (BL) behavioral assessment, the surgical procedure for chronic constriction of the sciatic nerve was completed as previously described (Bennett and Xie, 1988) , but modified for mouse (Murphy et al., 1999) . In brief, the mice were anesthetized with isoflurane-(induction 5% vol. followed by 2.0% in oxygen), and the mid to lower back and the dorsal left thigh were shaved and cleaned with 75% ethanol. Using aseptic procedures, the sciatic nerve was carefully isolated, and loosely ligated with 3 segments of 5-0 chromic gut sutures (Ethicon, Somerville, NJ). Sham surgery was identical to CCI surgery, but without the loose nerve ligation. The overlying muscle was closed with (1) 4-0 sterile silk suture (Ethicon, Somerville, NJ), and animals recovered from anesthesia within approximately 5 min. Mice were randomly assigned to either CCI or sham surgical group. Mice in both groups were re-assessed for allodynia and thermal hyperalgesia, as described above. Subjects were tested with drug or vehicle between 5 and 18 days after surgery.
Drug discrimination
A separate group of 12 male C57BL/6J mice, trained to discriminate CP55,940 (0.1 mg/kg) from vehicle (30 min pretreatment time), was used to test whether JZL184 or MJN110
would substitute for the training drug. Training and testing were conducted according to general procedures described previously (Long et al., 2009b; Walentiny et al., 2013 
Locomotor activity
Locomotor activity was assessed in naïve mice placed individually in a clear, dimly lit Plexiglas box (42.7×21.0×20.4 cm) 120 min after injection of JZL184 or MJN110. Activity was monitored for 60 min using Anymaze (Stoelting, Wood Dale, Illinois) software, as described previously (Ignatowska-Jankowska et al., 2014) . Distance travelled, running speed, and time spent mobile were measured.
Triad assay
Mice were housed individually overnight. Subjects were administered vehicle or MJN110
(5 mg/kg) and 2, 4 and 24 h later were sequentially assessed in the following three procedures:
bar test (catalepsy), tail withdrawal test, and rectal temperature. Testing was performed according to previously described procedures (Long et al., 2009b; Schlosburg et al., 2010; IgnatowskaJankowska, 2014) , as detailed in supplementary methods.
This article has not been copyedited and formatted. The final version may differ from this version. Extraction and quantification of endocannabinoids by liquid chromatography-tandem mass spectrometry 2-AG, arachidonic acid, AEA, PEA and OEA levels were quantified from the whole brain of C57BL/6J mice after acute treatment with JZL184, MJN110, or vehicle. Because each MAGL inhibitor significantly attenuated CCI-induced thermal hyperalgesia at 3 h after injection, mice were euthanized via rapid decapitation (at 11:00-17:00 EST) at this time point. The brains were rapidly harvested, snap-frozen in dry ice, and stored at -80°C until the time of processing.
Tissues were further processed according to methods described previously (Ramesh et al., 2011; Ignatowska-Jankowska et al., 2014) . See supplementary methods for details.
Data analysis
All data are presented as mean ± standard error (SEM). For allodynia testing, psychometric behavioral analysis was performed to compute the log stiffness that would have resulted in the 50% paw withdrawal rate, as previously described (Treutwein and Strasburger, 1999) . Briefly, thresholds were estimated by fitting a Gaussian integral psychometric function to the observed withdrawal rates for each of the tested von Frey hairs, using a maximum-likelihood fitting method (Milligan et al., 2001; Wilkerson et al., 2012) . Data were analyzed using t-tests, 
Evaluation of MAGL inhibitors in the drug discrimination paradigm
The training dose of CP55,940 fully generalized for itself, while control injections of vehicle did not produce responding on the CP55,940 aperture ( Figure 3A ). Each MAGL inhibitor increased responding on the aperture associated with CP55,940 (0.1 mg/kg), but with different potencies ( Figure 3A ). JZL184 [F(4,27) = 9.57, p < 0.001; ED 50 (95% CL) = 24.9 (14.6-42. Significant increases in running speed were observed following 1.25 mg/kg and 2.5 mg/kg MJN110 and distance travelled was significantly increased by 1.25 mg/kg MJN110.
Assessment of acute cannabimimetic effects of MJN110
MJN110 (5 mg/kg) produced a small, but significant, increase in the tail withdrawal 
Evaluation of brain endocannabinoid levels following MAGL inhibitor treatment
The effects of acute administration of each MAGL inhibitor on 2-AG, arachidonic acid, and AEA levels in whole brain 3 h after drug administration are shown in Figure 5 . JZL184 
Discussion
The primary objective of the present study was to evaluate the impact of MAGL inhibition in reducing neuropathic pain versus eliciting common cannabimimetic side effects.
Here, we report that two MAGL inhibitors, JZL184 and MJN110, significantly reversed mechanical allodynia and thermal hyperalgesia in the CCI model of neuropathic pain. These effects were associated with elevated 2-AG and decreased free arachidonic acid in whole brain.
However, these inhibitors produced differential effects on locomotor activity at doses that produced full inhibition of MAGL.
Each MAGL inhibitor reversed CCI-induced bilateral allodynia and thermal hyperalgesia.
MJN110 was approximately 42 fold more potent than JZL184. The onset of the effects for each drug was 1 h, but MJN110 had a longer duration of action than JZL184. Pharmacokinetic differences between these drugs may account for the quicker onset of peak antinociceptive effects of MJN110 than the maximal effects of JZL184. The anti-allodynic effects of each inhibitor are likely mediated by 2-AG at cannabinoid receptors, as cannabinoid receptor antagonists blocked these anti-allodynic effects. However, given that 2-AG is a major source of arachidonic acid synthesis in brain , consequences related to reductions in this lipid may play a contributory role. For example, MAGL inhibition results in decreased levels of prostaglandins (Normura et al., 2011) , which are known to play an important role in inflammatory processes (Vane, 1971) . In contrast, neither of the MAGL inhibitors increased levels AEA, PEA, or OEA in brain.
In the present study, the anti-allodynic effects of both JZL184 and MJN110 required activation of CB 1 and CB 2 receptors. Likewise, other reports have demonstrated that both cannabinoid receptors play a necessary role in the antinociceptive effects of JZL184 in neuropathic pain models (Woodhams et al., 2012; Guindon et al., 2013) . The current findings demonstrating that CB 2 receptors play a necessary role in the mediation of the anti-allodynic effects of the MAGL inhibitors are divergent with previous mouse CCI studies from our laboratory in which the anti-allodynic effects of JZL184 and KML29 (Kinsey et al., 2009; Kinsey et al., 2013; Ignatowska-Jankowska et al., 2014) were mediated by CB 1 receptors, while CB 2 receptors did not play a necessary role. A key methodological difference between our previous and present studies is the type of suture used to ligate the sciatic nerve. The previous studies utilized silk sutures that elicited unilateral allodynia of the nerve-injured paw (Kinsey et al., 2009; Kinsey et al., 2010; Kinsey et al., 2011; Kinsey et al., 2013) , while in the present study, we utilized chromic gut suture that led to a bilateral allodynia. Reports of CCI-induced allodynia in rodents vary between unilateral and bilateral allodynia depending on the use of silk or chromic gut suture material, respectively (Paulson et al., 2000; Milligan et al., 2006; Jancalek et al., 2010) . Accordingly, the bilateral allodynia resulting from chromic gut suture may have elicited an increased inflammatory response that was ameliorated by 2-AG stimulation of CB 2 receptors.
Indeed, CB 2 receptor stimulation has been found to reduce levels of proinflammatory cytokines and secondary signaling molecules associated with neuropathic pain as well as increase levels of the anti-inflammatory cytokine IL-10 ( Wilkerson et al., 2012) .
In contrast to the necessary role of both cannabinoid receptors in mediating the antiallodynic effects of JZL184 and MJN110, reversal of CCI-induced thermal hyperalgesia required only the CB 1 receptor, while the CB 2 receptor was dispensable. Thus, the CB 2 receptor plays distinct roles in these two hallmark components of neuropathic pain, which is likely related to different mechanisms subserving the two pain modalities. Thermal hypersensitivity is mediated by lightly myelinated a-δ and myelinated C fibers, while mechanical allodynia is mediated by heavily myelinated a-β fibers (Woolf and Mannion, 1999; Costigan et al., 2009) . A disconnect between sensory and thermal alterations in pain modalities has been previously reported in a rat model of peripheral IL-1β induced allodynia and thermal hyperalgesia. In these studies a protein , 2014) . Likewise, in several animal models of pain, TRPV-1 antagonists are sufficient to block or reverse thermal hyperalgesia without producing anti-allodynic effects (Urano et al., 2012; Kim et al., 2014) . Therefore, the underpinnings of observed behavioral measurements of allodynia and thermal hyperalgesia are complex and warrant further studies.
Each MAGL inhibitor fully substituted for CP55,940 in the drug discrimination assay, which is in contrast to the effects of MAGL inhibitors in previously reported drug discrimination studies. Specifically, the selective MAGL inhibitor KML29 did not substitute for THC (Ignatowska-Jankowska et al., 2014) , which indicates differences between discriminative stimulus effects of those compounds. Moreover, JZL184 only partially substituted for THC (Long et al., 2009b ; however, the maximum doses of JZL184 tested in these respective prior studies were 40 mg/kg and 30 mg/kg. Higher doses were not assessed in those studies because of solubility constraints. However, in the present study, we found that administration of 100 mg/kg JZL184 in a double volume suspension fully substituted for CP55,940. The finding that MJN110 was more potent than JZL184, is consistent with its lower IC 50 for MAGL inhibition (Chang et al., 2012; Niphakis et al., 2013) . For each inhibitor, substitution/partial substitution occurred at doses that also elicited significant increases of brain 2-AG, but not AEA, and in each case, interoceptive effects were blocked by rimonabant.
Although brain endocannabinoid levels were not assessed following 100 mg/kg JZL184, these results are consistent with the notion that the CP55,940-like discriminative stimulus effects of these MAGL inhibitors were mediated by 2-AG activation of the CB 1 receptor.
JZL184 has previously been found to produce a subset of effects in the tetrad assay (Long et al., 2009a; Long et al., 2009b; Ignatowska-Jankowska et al., 2014) , a paradigm that has been used to infer cannabimimetic activity (Little et al., 1988) . It is important to note that cannabinoid receptor agonists are generally more potent in the drug discrimination paradigm than the tetrad assay (Wiley et al., 1995a; Wiley et al., 1995b) , which is consistent with the current study.
JPET Fast Forward. Published on as DOI: 10.1124 at ASPET Journals on September 13, 2017 jpet.aspetjournals.org
Downloaded from
Specifically, JZL184 produced a small increase in the tail withdrawal latencies (Long et al., 2009 ) and decreases in spontaneous locomotor activity. Likewise, here we found that MJN110 produced a low magnitude of effect in the warm water tail withdrawal test. Interestingly, MJN110 did not produce hypomotility, but significantly increased running speed during the first 10 min of the test, which led to concomitant increases in distance travelled. Moreover, MJN110
did not produce hypothermic effects. The observations that MJN110 increased running speed are reminiscent with studies showing that low doses of THC and CP55,940 stimulate locomotor behavior (Anderson et al., 1975; Evans et al., 1976; McGregor et al., 1996) .
As JZL184 and MJN110 elevated 2-AG in whole brain to a similar degree, the cause of the differential effects of these drugs on locomotor activity remains an open question. One possibility is related to their off-target effects. Specifically, JZL184 inhibits FAAH, albeit with considerable less potency than its inhibition of MAGL (Long et al., 2009b) . Nonetheless, acute administration of JZL184 does not lead to an increase in brain AEA levels. MJN110 also inhibits alpha/beta hydrolase domain 6 (ABHD6) (Niphakis et al., 2013) , a serine hydrolase that is postsynpatically located and known to metabolize 2-AG (Blankman et al., 2007) . Another possibility is that pharmacokinetic differences may have affected absorption and distribution of each drug.
Accordingly, these drugs may have led to differential rates of 2-AG elevation in specific neural circuits that mediate locomotor activity.
In conclusion, MAGL inhibitors reliably reverse nociceptive behaviors in the CCI model of neuropathic pain with reduced cannabimimetic side effects. While both JZL184 and MJN110 produced cannabimimetic interoceptive effects in the drug discrimination paradigm, they produced opposing effects on locomotor behavior. In particular, MJN110 reversed nociceptive behavior in the CCI model of neuropathic pain with a two fold greater potency than required to substitute for CP55,940 in the drug discrimination paradigm, and did not produce hypomotility, catalepsy, or hypothermia. More generally, the present study taken together with previous work (Long et al., 2009b; Kinsey et al., 2009; Schlosburg et al., 2010; Guindon et al., 2011; Guindon et al., 2013; Kinsey et al., 2013; Ignatowska-Jankowska, 2014) suggests that MAGL inhibition represents a promising strategy to alleviate neuropathic pain with decreased incidence of cannabimimetic side effects.
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